

Inventor: Heidi Sisniega Barroso et al.

Appln. No. Unassigned

Docket No.: 031309-003

PCK/MXM

Date: October 2, 2000

Title: PROMOTER AND CONSTRUCTIONS FOR EXPRESSION OF RECOMBINANT PROTEINS
IN FILAMENTOUS FUNGI



The following was/were received in the U.S. Patent and Trademark Office on the date stamped hereon:


- ☒ Utility Patent Application Transmittal
- ☐ Design Patent Application Transmittal
- ☐ Continuing Prosecution Application Request
- ☐ Provisional Application Cover Sheet
- ☐ Provisional Application Transmittal
- ☐ Continuation/Divisional Application (Rule 1.53(b)) with copy of application
- ☐ Request for Continued Examination

INCLUDING:

- ☒ Specification (pages 1 - 47)
- ☒ Claims (claim(s) 1 - 35, 5 pgs.)
- ☒ Drawings (Fig(s). 1 - 12, 18 pgs.)

- ☒ Abstract of the Disclosure
- ☒ Executed Declaration/Power of Attorney
- ☐ Unexecuted Declaration/Power of Attorney
- ☐ Assignment/Assignment Recordation Form Cover Sheet (PTO-1595)
- ☐ Claim for Convention Priority w/_ certified copy(s)
- ☒ Preliminary Amendment
- ☒ Information Discl. Statement Transmittal Letter
- ☒ Information Disclosure Citation (PTO-1449)
- ☒ Information Disclosure Statement w/_ document(s)
- ☐ Petition for _ Month Extension of Time
- ☐ Constructive Petition for Extensions of Time

- ☒ Check for \$ 2,078.00 is enclosed
- ☐ Check for \$ _ is enclosed
- ☐ Charge \$ _ to Deposit Account
- ☒ Sequence Listing in computer readable form and paper copy
- ☒ Copy of International Search Report
- ☒ Copy of International Preliminary Examination Report
- ☐



(10/00)

BEST AVAILABLE COPY



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of

Heidi Sisniega Barroso et al.

Application No.: 09/647,543

Filing Date: October 2, 2000

Title: PROMOTER AND CONSTRUCTIONS FOR EXPRESSION OF RECOMBINANT PROTEINS IN FILAMENTOUS FUNGI

Group Art Unit: 1636

Examiner: Konstantina T Katcheves

Confirmation No.: 8353

AMENDMENT/REPLY TRANSMITTAL LETTER

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

Sir:

Enclosed is a reply for the above-identified patent application.

- ☒ A Petition for Extension of Time is also enclosed.
- ☐ Terminal Disclaimer(s) and the ☐ \$65.00 (2814) ☐ \$130.00 (1814) fee per Disclaimer due under 37 C.F.R. § 1.20(d) are also enclosed.
- ☒ Also enclosed is/are 1) Paper Copy of Sequence Listing; 2) Computer Readable Form (CRF) of Sequence Listing; 3) Copy of Date-Stamped Postcard dated October 2, 2000.
- ☐ Small entity status is hereby claimed.
- ☐ Applicant(s) requests continued examination under 37 C.F.R. § 1.114 and enclose the ☐ \$395.00 (2801) ☐ \$790.00 (1801) fee due under 37 C.F.R. § 1.17(e).
- ☐ Applicant(s) requests that any previously unentered after final amendments not be entered. Continued examination is requested based on the enclosed documents identified above.
- ☐ Applicant(s) previously submitted _____
on _____
for which continued examination is requested.
- ☐ Applicant(s) requests suspension of action by the Office until at least _____, which does not exceed three months from the filing of this RCE, in accordance with 37 C.F.R. § 1.103(c). The required fee under 37 C.F.R. § 1.17(i) is enclosed.
- ☐ A Request for Entry and Consideration of Submission under 37 C.F.R. § 1.129(a) (1809/2809) is also enclosed.

- ☒ No additional claim fee is required.
- ☐ An additional claim fee is required, and is calculated as shown below.

AMENDED CLAIMS					
	No. of Claims	Highest No. of Claims Previously Paid For	Extra Claims	Rate	Additional Fee
Total Claims	61	MINUS 61 =	0	x \$50.00 (1202) =	\$ 0.00
Independent Claims	9	MINUS 9 =	0	x \$200.00 (1201) =	\$ 0.00
If Amendment adds multiple dependent claims, add \$360.00 (1203)					
Total Claim Amendment Fee					\$ 0.00
<input type="checkbox"/> Small Entity Status claimed - subtract 50% of Total Claim Amendment Fee					\$ 0.00
TOTAL ADDITIONAL CLAIM FEE DUE FOR THIS AMENDMENT					\$ 0.00

- ☐ A check in the amount of _____ is enclosed for the fee due.
- ☐ Charge _____ to Deposit Account No. 02-4800.
- ☐ Charge _____ to credit card. Form PTO-2038 is attached.

The Director is hereby authorized to charge any appropriate fees under 37 C.F.R. §§ 1.16, 1.17, 1.20(d) and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 02-4800. This paper is submitted in duplicate.


Respectfully submitted,

BUCHANAN INGERSOLL PC

P.O. Box 1404
Alexandria, Virginia 22313-1404
(703) 836-6620

Date: November 2, 2005

By



Christopher L. North, Ph.D.
Registration No. 50,433